Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
2010-2-10
pubmed:abstractText
Recent advances in the knowledge of the EGFR pathway have revealed its contribution to distinct immune/inflammatory functions of the epidermis. The purpose of our study was to evaluate the role of EGFR in the regulation of keratinocyte GM-CSF expression. In cultured human keratinocytes, proinflammatory cytokines synergized with TGF-alpha to induce GM-CSF expression. Accordingly, high epidermal levels of EGFR activation are associated with enhanced expression of GM-CSF in lesional skin of patients with psoriasis or allergic contact dermatitis. In cultured keratinocytes, pharmacological inhibition of EGFR activity reduced GM-CSF promoter transactivation, whereas genetic inhibition of AP-1 reduced expression of GM-CSF. Furthermore, EGFR activation enhanced TNF-alpha-induced c-Jun phosphorylation and DNA binding, whereas c-Jun silencing reduced GM-CSF expression. Using two different mouse models, we showed that the lack of a functional EGFR pathway was associated with reduced cytokine-induced phosphorylation of ERK1/2, JNK1/2, c-Jun and reduced keratinocyte-derived GM-CSF expression both in vitro and in vivo. Finally, the analysis of GM-CSF expression in the skin of cancer patients treated with anti EGFR drugs showed an association between ERK activity, c-Jun phosphorylation, and epidermal GM-CSF expression. These data demonstrate that the EGFR pathway is critical for the upregulation of keratinocyte GM-CSF expression under conditions of cytokine stimulation.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Mar
pubmed:issn
1523-1747
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
130
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
682-93
pubmed:meshHeading
pubmed-meshheading:19890352-Adult, pubmed-meshheading:19890352-Aged, pubmed-meshheading:19890352-Animals, pubmed-meshheading:19890352-Antibodies, Monoclonal, pubmed-meshheading:19890352-Antineoplastic Agents, pubmed-meshheading:19890352-Cells, Cultured, pubmed-meshheading:19890352-Dermatitis, Atopic, pubmed-meshheading:19890352-Drug Eruptions, pubmed-meshheading:19890352-Female, pubmed-meshheading:19890352-Granulocyte-Macrophage Colony-Stimulating Factor, pubmed-meshheading:19890352-Humans, pubmed-meshheading:19890352-Interferon-gamma, pubmed-meshheading:19890352-JNK Mitogen-Activated Protein Kinases, pubmed-meshheading:19890352-Keratinocytes, pubmed-meshheading:19890352-MAP Kinase Signaling System, pubmed-meshheading:19890352-Male, pubmed-meshheading:19890352-Mice, pubmed-meshheading:19890352-Mice, Inbred Strains, pubmed-meshheading:19890352-Mice, Mutant Strains, pubmed-meshheading:19890352-Middle Aged, pubmed-meshheading:19890352-Phosphorylation, pubmed-meshheading:19890352-Psoriasis, pubmed-meshheading:19890352-Receptor, Epidermal Growth Factor, pubmed-meshheading:19890352-Transcription, Genetic, pubmed-meshheading:19890352-Transforming Growth Factor alpha
pubmed:year
2010
pubmed:articleTitle
EGFR regulates the expression of keratinocyte-derived granulocyte/macrophage colony-stimulating factor in vitro and in vivo.
pubmed:affiliation
Laboratory of Cancer Biology and Genetics, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA. masciaf@mail.nih.gov
pubmed:publicationType
Journal Article, In Vitro, Research Support, Non-U.S. Gov't, Research Support, N.I.H., Intramural